Soligenix, Inc. (NASDAQ:SNGX) Short Interest Down 50.6% in June

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 19,700 shares, a decrease of 50.6% from the June 15th total of 39,900 shares. Currently, 2.0% of the shares of the company are sold short. Based on an average trading volume of 2,530,000 shares, the short-interest ratio is currently 0.0 days.

Soligenix Stock Down 5.4 %

NASDAQ:SNGX opened at $7.24 on Friday. The company has a 50 day moving average price of $4.78 and a 200-day moving average price of $8.30. Soligenix has a 1-year low of $1.83 and a 1-year high of $32.00.

Soligenix (NASDAQ:SNGX) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($2.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.20) by $0.32. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,025.66% and a negative return on equity of 198.36%. Analysts forecast that Soligenix will post -9.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Soligenix stock. OLD National Bancorp IN acquired a new position in shares of Soligenix, Inc. (NASDAQ:SNGX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. OLD National Bancorp IN owned 1.01% of Soligenix as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.